Bli medlem
Bli medlem

Du är här


Galapagos NV: Galapagos to present promising findings in cystic fibrosis programs at NACFC 2015

Five poster presentations cover progress and depth

of discovery and development efforts in CF

Mechelen, Belgium; 8 October 2015 -
Galapagos NV (Euronext&NASDAQ: GLPG) is present with a strong delegation
presenting or contributing to five posters at the
North American Cystic Fibrosis Conference (NACFC) in Phoenix this week.

Thursday, 8 October 11.50 AM - 1.50 PM MST

All posters

Friday, 9 October 7.30 AM - 8.45 AM

Poster 50
Potentiators: how do they impact the fate of CFTR during biogenesis?

Insights are presented on the contribution of GLPG1837 to the rescue of
F508del CFTR

Poster 70
Insight into the mechanisms of correctors and potentiators

Galapagos and Abbvie developed new tools to better understand the mechanism of
action of correctors and potentiators in its CF portfolio

Poster 62
Using BLISS analysis to categorize corrector-corrector interactions

Galapagos and AbbVie disclose the usage of a modelling tool to categorize
interactions between candidate corrector compounds in their CF program

Poster 258
Safety, tolerability and pharmacokinetics of a novel CFTR Potentiator GLPG1837
in healthy volunteers

Galapagos presents safety and tolerability of GLPG1837 in healthy human
volunteers, paving the path for the Phase 2 study in Class III mutation
patients to start by end 2015. More information on this poster will be
published later during the conference.
Saturday, 10 October 7.30 AM - 8.45 AM

Poster 219
Novel Potentiators Augment Efficacy of Translational Readthrough in CFTR
Nonsense Mutations

Promising pre-clinical data using Galapagos potentiators on Class I (nonsense)
CFTR mutations is presented

These posters will be made available on the Galapagos website,,
shortly following the presentation sessions.

The North American Cystic Fibrosis Conference is sponsored by the Cystic
Fibrosis Foundation:

About cystic fibrosis (CF)

CF is a rare, life-threatening, genetic disease that affects approximately
80,000 patients worldwide and approximately 30,000 patients in the United
States. CF is a chronic disease that affects the lungs and digestive system.
CF patients, with significantly impaired quality of life, have an average
lifespan approximately 50% shorter than the population average, with the
median age of death at 27. There currently is no cure for CF. CF patients
require lifelong treatment with multiple daily medications, frequent
hospitalizations and ultimately lung transplant, which is life-extending but
not curative. CF is caused by a mutation in the gene for the CFTR protein,
which results in abnormal transport of chloride across cell membranes.
Transport of chloride is required for effective hydration of epithelial
surfaces in many organs of the body. Normal CFTR channel moves chloride ions
to outside of the cell. Mutant CFTR channel does not move chloride ions,
causing sticky mucous to build up on the outside of the cell. CFTR
dysfunction results in dehydration of dependent epithelial surfaces, leading
to damage of the affected tissues and subsequent disease, such as lung
disease, malabsorption in the intestinal tract and pancreatic insufficiency.

About Galapagos

Galapagos (Euronext&NASDAQ: GLPG) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action, with a pipeline comprising three Phase 2 programs, two
Phase 1 trials, five pre-clinical studies, and 20 discovery small-molecule
and antibody programs in cystic fibrosis, inflammation, and other
indications. Filgotinib is an orally-available, selective inhibitor of JAK1
for the treatment of rheumatoid arthritis and potentially other inflammatory
diseases. Galapagos has reported good activity and a favorable safety profile
in both the DARWIN 1 and 2 trials in RA. Galapagos is preparing to enter
Phase 3 studies in RA and to report Phase 2 topline results with filgotinib
in Phase 2 in Crohn's disease. In the field of cystic fibrosis, AbbVie and
Galapagos signed a collaboration agreement to develop and commercialize
molecules that address mutations in the CFTR gene. Potentiator GLPG1837 has
completed a Phase 1 trial, and corrector GLPG2222 is expected to enter Phase
1 by end 2015. GLPG1205, a first-in-class inhibitor of GPR84 and fully-owned
by Galapagos, will report topline results in Q4 2015 from a Phase 2
proof-of-concept trial in ulcerative colitis patients. GLPG1690, a fully
proprietary, first-in-class inhibitor of autotaxin, has shown favorable
safety in a Phase 1 trial and is expected to enter Phase 2 in idiopathic
pulmonary fibrosis. The Galapagos Group, including fee-for-service subsidiary
Fidelta, has approximately 400 employees, operating from its Mechelen,
Belgium headquarters and facilities in The Netherlands, France, and Croatia.
More info at


Galapagos NV

Elizabeth Goodwin, VP IR&Corporate Communications
Cell: +1 781 460 1784

Media inquiries:
Evelyn Fox, Director Communications
Tel: +31 6 53 591 999

Galapagos forward-looking statements

This release may contain forward-looking statements, including statements
regarding the promising findings demonstrated in the Company's product
candidates for cystic fibrosis. Galapagos cautions the reader that
forward-looking statements are not guarantees of future performance.
Forward-looking statements involve known and unknown risks, uncertainties and
other factors which might cause the actual results, financial condition and
liquidity, performance or achievements of Galapagos, or industry results, to
be materially different from any historic or future results, financial
conditions and liquidity, performance or achievements expressed or implied by
such forward-looking statements. In addition, even if Galapagos' results,
performance, financial condition and liquidity, and the development of the
industry in which it operates are consistent with such forward-looking
statements, they may not be predictive of results or developments in future
periods. Among the factors that may result in differences are the inherent
uncertainties associated with competitive developments, clinical trial and
product development activities and regulatory approval requirements
(including that data from Galapagos' ongoing clinical research programs in
cystic fibrosis may not support registration or further development of
potentiators and/or correctors due to safety, efficacy or other reasons),
Galapagos' reliance on collaborations with third parties (including its
collaboration partner, AbbVie, who may not devote sufficient resources to the
development and commercialization of the cystic fibrosis programs), and
estimating the commercial potential of our product candidates. A further
list and description of these risks, uncertainties and other risks can be
found in the company's Securities and Exchange Commission filing and reports,
including in the company's prospectus filed with the SEC on May 14, 2015 and
future filings and reports filed by the company with the Securities and
Exchange Commission. Given these uncertainties, the reader is advised not to
place any undue reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication of this
document. Galapagos expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based or that may affect the
likelihood that actual results will differ from those set forth in the
forward-looking statements, unless specifically required by law or


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.